{"schema_version":"secwatch.filing_event.v1","accession":"0001651308-25-000131","form_type":"8-K","ticker":"ONC","cik":"0001651308","company_name":"BeOne Medicines Ltd.","filed_at":"2025-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.565409+00:00","generated_at":"2026-05-17T19:32:10.107654+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"BeOne Medicines Q2 2025 revenues jump 42% to $1.3B; GAAP EPS $0.84","bullets":["Total revenues $1.315B vs $929M YoY (+42%); BRUKINSA revenues up 49% to $950M.","GAAP net income $94.3M ($0.84 diluted EPS/ADS) vs loss of $120.4M a year ago.","Non-GAAP diluted EPS $2.25, adjusted income from operations $274.9M (up 467% YoY).","Free cash flow positive $219.8M vs negative $205.5M in Q2 2024.","Company expects 20+ R&D milestones in next 18 months across hematology and solid tumors."],"urls":{"canonical":"https://secwatch.observer/filing/0001651308-25-000131","json":"https://secwatch.observer/filing/0001651308-25-000131.json","markdown":"https://secwatch.observer/filing/0001651308-25-000131.md","text":"https://secwatch.observer/filing/0001651308-25-000131.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1651308/000165130825000131/0001651308-25-000131-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1651308/000165130825000131/bgne-20250806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T19:32:10.107654+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}